In Vitro Generation of Megakaryocytes and Platelets from Human Embryonic Stem Cells and Induced Pluripotent Stem Cells

  • Naoya Takayama
  • Koji EtoEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 788)


Human embryonic stem cells (hESCs) represent a potential source of blood cells for transfusion therapies and a promising tool for studying the ontogeny of hematopoiesis. Moreover, human-induced pluripotent stem cells (hiPSCs), recently established by defined reprogramming factors expressed in somatic cells, represent a further source for the generation of hematopoietic cells. When undifferentiated hESCs or hiPSCs are cultured on either mesenchymal C3H10T1/2 cells or OP-9 stromal cells, they can be differentiated into a hematopoietic niche that concentrates hematopoietic progenitors, which we named “embryonic stem cell-derived sacs” (ES-sacs). We have optimized the in vitro culture condition for obtaining mature megakaryocytes derived from the hematopoietic progenitors within ES-sacs, which are then able to release platelets. These in vitro-generated platelets display integrin activation capability, indicating normal hemostatic function. This novel protocol thus provides a means of generating platelets from hESCs as well as hiPSCs, for the study of normal human thrombopoiesis and also thrombopoiesis in disease conditions using patient-specific hiPSCs.

Key words

Human ESCs Human iPSCs ES-sac Hematopoietic progenitor Megakaryocyte Platelet Transfusion 


  1. 1.
    Debili, N. et al. The Mpl-ligand or thrombopoietin or megakaryocyte growth and differentiative factor has both direct proliferative and differentiative activities on human megakaryocyte progenitors. Blood 86, 2516–25 (1995).PubMedGoogle Scholar
  2. 2.
    Schipper, L.F. et al. Differential maturation of megakaryocyte progenitor cells from cord blood and mobilized peripheral blood. Exp Hematol 31, 324–30 (2003).PubMedCrossRefGoogle Scholar
  3. 3.
    Matsunaga, T. et al. Ex vivo large-scale generation of human platelets from cord blood CD34+ cells. Stem Cells 24, 2877–87 (2006).PubMedCrossRefGoogle Scholar
  4. 4.
    Matsubara, Y. et al. Generation of megakaryocytes and platelets from human subcutaneous adipose tissues. Biochem Biophys Res Commun 378, 716–20 (2009).PubMedCrossRefGoogle Scholar
  5. 5.
    Thomson, J.A. et al. Embryonic stem cell lines derived from human blastocysts. Science 282, 1145–7 (1998).PubMedCrossRefGoogle Scholar
  6. 6.
    Vodyanik, M.A., Bork, J.A., Thomson, J.A. & Slukvin, II. Human embryonic stem cell-derived CD34+ cells: efficient production in the coculture with OP9 stromal cells and analysis of lymphohematopoietic potential. Blood 105, 617–26 (2005).Google Scholar
  7. 7.
    Wang, L. et al. Endothelial and hematopoietic cell fate of human embryonic stem cells originates from primitive endothelium with hemangioblastic properties. Immunity 21, 31–41 (2004).PubMedCrossRefGoogle Scholar
  8. 8.
    Takayama, N. et al. Generation of functional platelets from human embryonic stem cells in vitro via ES-sacs, VEGF-promoted structures that concentrate hematopoietic progenitors. Blood 111, 5298–306 (2008).PubMedCrossRefGoogle Scholar
  9. 9.
    Ma, F. et al. Generation of functional erythrocytes from human embryonic stem cell-derived definitive hematopoiesis. Proc Natl Acad Sci USA 105, 13087–92 (2008).PubMedCrossRefGoogle Scholar
  10. 10.
    Yokoyama, Y. et al. Derivation of functional mature neutrophils from human embryonic stem cells. Blood 113, 6584–92 (2009).PubMedCrossRefGoogle Scholar
  11. 11.
    Schiffer, C.A. Diagnosis and management of refractoriness to platelet transfusion. Blood Rev 15, 175–80 (2001).PubMedCrossRefGoogle Scholar
  12. 12.
    Suemori, H. et al. Efficient establishment of human embryonic stem cell lines and long-term maintenance with stable karyotype by enzymatic bulk passage. Biochem Biophys Res Commun 345, 926–32 (2006).PubMedCrossRefGoogle Scholar
  13. 13.
    Shattil, S.J., Hoxie, J.A., Cunningham, M. & Brass, L.F. Changes in the platelet membrane glycoprotein IIb.IIIa complex during platelet activation. J Biol Chem 260, 11107–14 (1985).Google Scholar
  14. 14.
    Hiroyama, T. et al. Long-lasting in vitro hematopoiesis derived from primate embryonic stem cells. Exp Hematol 34, 760–9 (2006).PubMedCrossRefGoogle Scholar
  15. 15.
    Nishikii, H. et al. Metalloproteinase regulation improves in vitro generation of efficacious platelets from mouse embryonic stem cells. J Exp Med 205, 1917–27 (2008).PubMedCrossRefGoogle Scholar
  16. 16.
    Bergmeier, W. et al. Metalloproteinase inhibitors improve the recovery and hemostatic function of in vitro-aged or -injured mouse platelets. Blood 102, 4229–35 (2003).PubMedCrossRefGoogle Scholar
  17. 17.
    Shattil, S.J. & Newman, P.J. Integrins: dynamic scaffolds for adhesion and signaling in platelets. Blood 104, 1606–15 (2004).PubMedCrossRefGoogle Scholar
  18. 18.
    Peerlinck, K. et al. MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man. Circulation 88, 1512–7 (1993).PubMedGoogle Scholar
  19. 19.
    Eto, K. et al. Megakaryocytes derived from embryonic stem cells implicate CalDAG-GEFI in integrin signaling. Proc Natl Acad Sci USA 99, 12819–24 (2002).PubMedCrossRefGoogle Scholar
  20. 20.
    Takayama, N. et al. Transient activation of c-MYC expression is critical for efficient platelet generation from human induced pluripotent stem cells. J Exp Med 207, 2817–30 (2010).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Clinical Application Department, Center for iPS Cell Research and Application (CiRA)Kyoto UniversityKyotoJapan
  2. 2.Clinical Application Department, Center for iPS Cell Research and Application (CiRA)Kyoto UniversityKyotoJapan

Personalised recommendations